Nasdaq Drops Accelrys, Affy, Caliper, Luminex from Biotech Index, adds Genomic Health, Solexa | GenomeWeb
This article has been updated from a previous version to clarify the ICB classification system that Nasdaq uses as part of its criteria for including companies in the Biotechnology Index.
 
NEW YORK, May 15 (GenomeWeb News) - A number of genomics firms have been dropped from the Nasdaq Biotechnology index as part of a semi-annual update, the exchange said on Friday.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.